BioArctic's founders intend to divest minor part of their shareholding

Rhea-AI Summary

BioArctic AB (Nasdaq Stockholm: BIOA-B) announced that its two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, plan to sell a minor portion of their shareholdings in the company. The company disclosed this information in compliance with EU Market Abuse Regulation requirements.

Positive

• None.

Negative

• Potential reduction in founders' ownership stake could signal decreased insider confidence

News Market Reaction

+1.94%

4 alerts

+1.94% News Effect

+$3M Valuation Impact

$177M Market Cap

0.1x Rel. Volume

On the day this news was published, BIOA gained 1.94%, reflecting a mild positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $177M at that time.

Data tracked by StockTitan Argus on the day of publication.

STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA-B) has been made aware that the company's two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, intend to divest a minor part of their respective shareholding.

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on September 3, 2025, at 5:35 p.m. CET.

For further information, please contact: 
Oskar Bosson, Vice President Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 70 410 71 80

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/bioarctic-s-founders-intend-to-divest-minor-part-of-their-shareholding,c4229359

The following files are available for download:

https://mb.cision.com/Main/9978/4229359/3647880.pdf

BioArctic's founders intend to divest minor part of their shareholding

View original content:https://www.prnewswire.com/news-releases/bioarctics-founders-intend-to-divest-minor-part-of-their-shareholding-302545484.html

SOURCE BioArctic

FAQ

What did BioArctic founders announce about their shareholdings on September 3, 2025?

BioArctic founders Lars Lannfelt and Pär Gellerfors announced their intention to sell a minor part of their respective shareholdings in the company.

Who are the main shareholders planning to reduce their stake in BioArctic?

The two founders of BioArctic, Lars Lannfelt and Pär Gellerfors, are the main shareholders planning to reduce their stakes.

When was BioArctic's share sale announcement made?

The announcement was made on September 3, 2025, at 5:35 p.m. CET.

How can investors contact BioArctic regarding the founders' share sale?

Investors can contact Oskar Bosson, Vice President Communications and Investor Relations, via email at oskar.bosson@bioarctic.com or telephone at +46 70 410 71 80.